Regeneron Pharmaceuticals (REGN) 10-Q31 Oct 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Oct. 23, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	000-19034
Entity Registrant Name	REGENERON PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	13-3444607
Entity Address, Address Line One	777 Old Saw Mill River Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591-6707
City Area Code	914
Local Phone Number	847-7000
Title of 12(b) Security	Common Stock - par value $.001 per share
Trading Symbol	REGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0000872589
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Class A Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		1,817,146
Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		108,072,385

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,011.8	$ 2,730
Marketable securities	7,784.7	8,114.8
Accounts receivable, net	6,107.1	5,667.3
Inventories	3,018	2,580.5
Prepaid expenses and other current assets	412	386.6
Total current assets	19,333.6	19,479.2
Marketable securities	8,490.9	5,396.5
Property, plant, and equipment, net	4,439.2	4,146.4
Intangible assets, net	1,120.1	1,038.6
Deferred tax assets	3,015.1	2,575.4
Other noncurrent assets	1,043	444.1
Total assets	37,441.9	33,080.2
Current liabilities:
Accounts payable	497.3	606.6
Accrued expenses and other current liabilities	2,536.5	2,357.9
Deferred revenue	627.2	458.9
Total current liabilities	3,661	3,423.4
Long-term debt	1,984	1,982.9
Finance lease liabilities	720	720
Deferred revenue	207.4	126.7
Other noncurrent liabilities	1,543.6	854.1
Total liabilities	8,116	7,107.1
Stockholders' equity:
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none	0	0
Additional paid-in capital	12,702.8	11,354
Retained earnings	30,755.2	27,260.3
Accumulated other comprehensive income (loss)	60.2	(80.9)
Treasury Stock, at cost; 27.0 shares in 2024 and 25.5 shares in 2023	(14,192.4)	(12,560.4)
Total stockholders' equity	29,325.9	25,973.1
Total liabilities and stockholders' equity	37,441.9	33,080.2
Class A Stock
Stockholders' equity:
Common stock	0	0
Common Stock
Stockholders' equity:
Common stock	$ 0.1	$ 0.1

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2024	Dec. 31, 2023
Stockholders' Equity Attributable to Parent [Abstract]
Preferred Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized (in shares)	30	30
Preferred Stock, shares issued (in shares)	0	0
Preferred Stock, shares outstanding (in shares)	0	0
Treasury stock (in shares)	27	25.5
Class A Stock
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized (in shares)	40	40
Common Stock, shares outstanding (in shares)	1.8	1.8
Common Stock, shares issued (in shares)	1.8	1.8
Common Stock
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized (in shares)	320	320
Common Stock, shares issued (in shares)	135.3	133.1

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Revenues	$ 3,720.7	$ 3,362.7	$ 10,412.8	$ 9,682.9
Expenses:
Research and development	1,271.5	1,075.3	3,719.9	3,261.8
Acquired in-process research and development	56.2	100	87.2	156.1
Selling, general, and administrative	714.4	640.5	2,162.2	1,893.6
Other operating expense (income), net	8	(0.5)	37.9	(1.6)
Total Expenses	2,541.2	2,251.7	7,412.3	6,608.7
Income from operations	1,179.5	1,111	3,000.5	3,074.2
Other income (expense):
Other income (expense), net	327.3	17.6	866	32.2
Interest expense	(13.8)	(17.8)	(44.7)	(54.7)
Total other income (expense)	313.5	(0.2)	821.3	(22.5)
Income before income taxes	1,493	1,110.8	3,821.8	3,051.7
Income tax expense	152.4	103	326.9	257.7
Net income	$ 1,340.6	$ 1,007.8	$ 3,494.9	$ 2,794
Net income per share - basic (in dollars per share)	$ 12.40	$ 9.48	$ 32.36	$ 26.16
Net income per share - diluted (in dollars per share)	$ 11.54	$ 8.89	$ 30.23	$ 24.57
Weighted average shares outstanding - basic (in shares)	108.1	106.3	108	106.8
Weighted average shares outstanding - diluted (in shares)	116.2	113.4	115.6	113.7
Statements of Comprehensive Income
Net income	$ 1,340.6	$ 1,007.8	$ 3,494.9	$ 2,794
Other comprehensive income (loss), net of tax:
Unrealized gain on debt securities	128.2	21.3	139.6	62.8
Gain (loss) on foreign currency translation	1.9	(0.4)	1.5	(0.8)
Comprehensive income	1,470.7	1,028.7	3,636	2,856
Net product sales
Revenues:
Revenues	1,946.4	1,786.1	5,626.3	5,226.2
Expenses:
Cost of goods sold, collaboration and contract manufacturing	262.3	224.5	760.5	625.3
Collaboration revenue
Revenues:
Revenues	1,660.1	1,438.3	4,450.9	4,133.1
Other revenue
Revenues:
Revenues	114.2	138.3	335.6	323.6
Cost of collaboration and contract manufacturing
Expenses:
Cost of goods sold, collaboration and contract manufacturing	$ 228.8	$ 211.9	$ 644.6	$ 673.5

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Class A Stock	Class A Stock Common Stock
Beginning Balance (in shares) at Dec. 31, 2022		130.4						1.8
Beginning Balance, treasury (in shares) at Dec. 31, 2022						(22.6)
Beginning Balance at Dec. 31, 2022	$ 22,664	$ 0.1	$ 9,949.3	$ 23,306.7	$ (238.8)	$ (10,353.3)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)		1.1
Issuance of Common Stock for equity awards granted under long-term incentive plans	491.3		491.3
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)		(0.1)
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	(99.2)		(99.2)
Issuance/distribution of Common Stock for 401(k) Savings Plan	20.6		18.9			$ 1.7
Repurchases of Common Stock (in shares)						(0.9)
Repurchases of Common Stock	(693.9)					$ (693.9)
Stock-based compensation charges	237.4		237.4
Net income	817.8			817.8
Other comprehensive income (loss), net of tax	57.2				57.2
Ending Balance (in shares) at Mar. 31, 2023		131.4						1.8
Ending Balance, treasury (in shares) at Mar. 31, 2023						(23.5)
Ending Balance at Mar. 31, 2023	23,495.2	$ 0.1	10,597.7	24,124.5	(181.6)	$ (11,045.5)		$ 0
Beginning Balance (in shares) at Dec. 31, 2022		130.4						1.8
Beginning Balance, treasury (in shares) at Dec. 31, 2022						(22.6)
Beginning Balance at Dec. 31, 2022	22,664	$ 0.1	9,949.3	23,306.7	(238.8)	$ (10,353.3)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,794
Ending Balance (in shares) at Sep. 30, 2023		132.1						1.8
Ending Balance, treasury (in shares) at Sep. 30, 2023						(25.1)
Ending Balance at Sep. 30, 2023	24,904.4	$ 0.1	11,251.5	26,100.7	(176.8)	$ (12,271.1)		$ 0
Beginning Balance (in shares) at Mar. 31, 2023		131.4						1.8
Beginning Balance, treasury (in shares) at Mar. 31, 2023						(23.5)
Beginning Balance at Mar. 31, 2023	23,495.2	$ 0.1	10,597.7	24,124.5	(181.6)	$ (11,045.5)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)		0.2
Issuance of Common Stock for equity awards granted under long-term incentive plans	80.7		80.7
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	(14)		(14)
Issuance/distribution of Common Stock for 401(k) Savings Plan	18.5		16.1			$ 2.4
Repurchases of Common Stock (in shares)						(1)
Repurchases of Common Stock	(722.8)					$ (722.8)
Stock-based compensation charges	208		208
Net income	968.4			968.4
Other comprehensive income (loss), net of tax	(16.1)				(16.1)
Ending Balance (in shares) at Jun. 30, 2023		131.6						1.8
Ending Balance, treasury (in shares) at Jun. 30, 2023						(24.5)
Ending Balance at Jun. 30, 2023	24,017.9	$ 0.1	10,888.5	25,092.9	(197.7)	$ (11,765.9)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)		0.7
Issuance of Common Stock for equity awards granted under long-term incentive plans	268.9		268.9
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)		(0.2)
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	(129.4)		(129.4)
Issuance/distribution of Common Stock for 401(k) Savings Plan	18		16.1			$ 1.9
Repurchases of Common Stock (in shares)						(0.6)
Repurchases of Common Stock	(507.1)					$ (507.1)
Stock-based compensation charges	207.4		207.4
Net income	1,007.8			1,007.8
Other comprehensive income (loss), net of tax	20.9				20.9
Ending Balance (in shares) at Sep. 30, 2023		132.1						1.8
Ending Balance, treasury (in shares) at Sep. 30, 2023						(25.1)
Ending Balance at Sep. 30, 2023	$ 24,904.4	$ 0.1	11,251.5	26,100.7	(176.8)	$ (12,271.1)		$ 0
Beginning Balance (in shares) at Dec. 31, 2023		133.1					1.8	1.8
Beginning Balance, treasury (in shares) at Dec. 31, 2023	(25.5)					(25.5)
Beginning Balance at Dec. 31, 2023	$ 25,973.1	$ 0.1	11,354	27,260.3	(80.9)	$ (12,560.4)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)		1.5
Issuance of Common Stock for equity awards granted under long-term incentive plans	672.4		672.4
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)		(0.4)
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	(335.9)		(335.9)
Issuance/distribution of Common Stock for 401(k) Savings Plan	20.5		18.8			$ 1.7
Repurchases of Common Stock (in shares)						(0.3)
Repurchases of Common Stock	(298)					$ (298)
Stock-based compensation charges	233.3		233.3
Net income	722			722
Other comprehensive income (loss), net of tax	3.7				3.7
Ending Balance (in shares) at Mar. 31, 2024		134.2						1.8
Ending Balance, treasury (in shares) at Mar. 31, 2024						(25.8)
Ending Balance at Mar. 31, 2024	$ 26,991.1	$ 0.1	11,942.6	27,982.3	(77.2)	$ (12,856.7)		$ 0
Beginning Balance (in shares) at Dec. 31, 2023		133.1					1.8	1.8
Beginning Balance, treasury (in shares) at Dec. 31, 2023	(25.5)					(25.5)
Beginning Balance at Dec. 31, 2023	$ 25,973.1	$ 0.1	11,354	27,260.3	(80.9)	$ (12,560.4)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 3,494.9
Ending Balance (in shares) at Sep. 30, 2024		135.3					1.8	1.8
Ending Balance, treasury (in shares) at Sep. 30, 2024	(27)					(27)
Ending Balance at Sep. 30, 2024	$ 29,325.9	$ 0.1	12,702.8	30,755.2	60.2	$ (14,192.4)		$ 0
Beginning Balance (in shares) at Mar. 31, 2024		134.2						1.8
Beginning Balance, treasury (in shares) at Mar. 31, 2024						(25.8)
Beginning Balance at Mar. 31, 2024	26,991.1	$ 0.1	11,942.6	27,982.3	(77.2)	$ (12,856.7)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)		1
Issuance of Common Stock for equity awards granted under long-term incentive plans	436.5		436.5
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)		(0.4)
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	(311.8)		(311.8)
Issuance/distribution of Common Stock for 401(k) Savings Plan	21.8		19.6			$ 2.2
Repurchases of Common Stock (in shares)						(0.6)
Repurchases of Common Stock	(601.4)					$ (601.4)
Stock-based compensation charges	230		230
Net income	1,432.3			1,432.3
Other comprehensive income (loss), net of tax	7.3				7.3
Ending Balance (in shares) at Jun. 30, 2024		134.8						1.8
Ending Balance, treasury (in shares) at Jun. 30, 2024						(26.4)
Ending Balance at Jun. 30, 2024	28,205.8	$ 0.1	12,316.9	29,414.6	(69.9)	$ (13,455.9)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)		0.6
Issuance of Common Stock for equity awards granted under long-term incentive plans	255.7		255.7
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)		(0.1)
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	(120.2)		(120.2)
Issuance/distribution of Common Stock for 401(k) Savings Plan	21.8		20			$ 1.8
Repurchases of Common Stock (in shares)						(0.6)
Repurchases of Common Stock	(738.3)					$ (738.3)
Stock-based compensation charges	230.4		230.4
Net income	1,340.6			1,340.6
Other comprehensive income (loss), net of tax	$ 130.1				130.1
Ending Balance (in shares) at Sep. 30, 2024		135.3					1.8	1.8
Ending Balance, treasury (in shares) at Sep. 30, 2024	(27)					(27)
Ending Balance at Sep. 30, 2024	$ 29,325.9	$ 0.1	$ 12,702.8	$ 30,755.2	$ 60.2	$ (14,192.4)		$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income	$ 3,494.9	$ 2,794
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	356.5	308
Stock-based compensation expense	678.4	644.6
(Gains) losses on marketable and other securities, net	(331.2)	324.5
Other non-cash items, net	(31.9)	17.4
Deferred income taxes	(477.1)	(551.5)
Changes in assets and liabilities:
Increase in accounts receivable	(436.2)	(256.1)
Increase in inventories	(502)	(224.4)
Increase in prepaid expenses and other assets	(352.2)	(284.4)
Increase (decrease) in deferred revenue	249	(5.1)
Increase in accounts payable, accrued expenses, and other liabilities	509.5	737.3
Total adjustments	(337.2)	710.3
Net cash provided by operating activities	3,157.7	3,504.3
Cash flows from investing activities:
Purchases of marketable and other securities	(14,664.5)	(9,514.2)
Sales or maturities of marketable and other securities	12,445.3	7,059.3
Capital expenditures	(556.3)	(467.2)
Proceeds from sale of property, plant, and equipment	20.1	0
Payments for Libtayo intangible asset	(58.3)	(145.7)
Acquisitions, net of cash acquired	(5)	(51.1)
Net cash used in investing activities	(2,818.7)	(3,118.9)
Cash flows from financing activities:
Proceeds from issuance of Common Stock	1,374.4	844.5
Payments in connection with Common Stock tendered for employee tax obligations	(775.7)	(242.5)
Repurchases of Common Stock	(1,630.3)	(1,946)
Other	(33.4)	0
Net cash used in financing activities	(1,065)	(1,344)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	0	(0.6)
Net decrease in cash, cash equivalents, and restricted cash	(726)	(959.2)
Cash, cash equivalents, and restricted cash at beginning of period	2,737.8	3,119.4
Cash, cash equivalents, and restricted cash at end of period	$ 2,011.8	$ 2,160.2

Interim Financial Statements

Interim Financial Statements	9 Months Ended
Interim Financial Statements	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Financial Statements	Interim Financial Statements Basis of Presentation The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December 31, 2023 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Recently Issued Accounting Standards In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures . The amendments require disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in Accounting Standards Codification 280, Segment Reporting . The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements. In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures . The amendments require (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.

Product Sales

Product Sales	9 Months Ended
Product Sales	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Product Sales	Product Sales Net product sales consist of the following: Three Months Ended Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 EYLEA HD ® U.S. $ 392.3 $ 42.7 $ 896.5 $ 42.7 EYLEA ® U.S. 1,144.6 1,448.2 3,576.7 4,382.1 Total EYLEA HD and EYLEA U.S. 1,536.9 1,490.9 4,473.2 4,424.8 Libtayo ® U.S. 194.5 144.1 536.1 384.0 Libtayo Rest of world 94.1 88.3 313.8 235.3 Total Libtayo Global 288.6 232.4 849.9 619.3 Praluent ® U.S. 52.9 40.4 179.0 121.1 Evkeeza ® U.S. 32.4 19.1 87.6 53.3 Inmazeb ® Global 35.6 3.3 36.6 7.7 $ 1,946.4 $ 1,786.1 $ 5,626.3 $ 5,226.2 As of September 30, 2024 and December 31, 2023, the Company had $4.142 billion and $3.888 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net. The Company had product sales to certain customers that each accounted for more than 10% of total gross product revenue for the three and nine months ended September 30, 2024 and 2023. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows: Three Months Ended September 30, Nine Months Ended 2024 2023 2024 2023 Besse Medical, a subsidiary of Cencora, Inc. 51 % 53 % 51 % 52 % McKesson Corporation 24 % 24 % 24 % 25 %

Collaboration, License, and Oth

Collaboration, License, and Other Agreements	9 Months Ended
Collaboration, License, and Other Agreements	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Collaboration, License, and Other Agreements	Collaboration, License, and Other Agreements a. Sanofi The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies, which currently consists of Dupixent ® (dupilumab), Kevzara ® (sarilumab), and itepekimab . Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi (i.e., "development balance") based on the Company's share of collaboration profits; however, the Company is only required to apply 20% of its share of profits from the collaboration each calendar quarter to reimburse Sanofi for these development expenses. As of September 30, 2024, the Company's contingent reimbursement obligation to Sanofi under the collaboration was approximately $1.810 billion. Sanofi leads commercialization activities for products under the collaboration, subject to the Company's right to co-commercialize such products. During the three months ended September 30, 2023, the Company earned the final $50.0 million sales-based milestone from Sanofi upon aggregate annual sales of antibodies outside the United States exceeding $3.0 billion on a rolling twelve-month basis. Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Regeneron's share of profits Collaboration revenue $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Sales-based milestones earned Collaboration revenue $ — $ 50.0 $ — $ 50.0 Reimbursement for manufacturing of commercial supplies Collaboration revenue $ 175.1 $ 151.5 $ 438.2 $ 506.0 Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses (R&D expense) $ (7.8) $ (25.8) $ (35.5) $ (66.7) Reimbursement of commercialization-related expenses Reduction of SG&A expense $ 169.0 $ 135.5 $ 459.3 $ 384.0 The following table summarizes contract balances in connection with the Company's Sanofi collaboration: September 30, December 31, (In millions) 2024 2023 Accounts receivable, net $ 1,270.5 $ 1,029.1 Deferred revenue $ 621.4 $ 427.7 b. Bayer The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA 8 mg (aflibercept 8 mg) and EYLEA (aflibercept) outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. Bayer is responsible for commercialization activities outside the United States, and the companies share equally in profits from such sales. Within the United States, the Company is responsible for commercialization and retains profits from such sales. Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Regeneron's share of profits Collaboration revenue $ 367.6 $ 349.9 $ 1,054.5 $ 1,031.0 Reimbursement for manufacturing of ex-U.S. commercial supplies Collaboration revenue $ 23.2 $ 27.2 $ 67.4 $ 79.7 Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses (R&D expense) $ (11.8) $ (9.7) $ (35.2) $ (35.1) The following table summarizes contract balances in connection with the Company's Bayer collaboration: September 30, December 31, (In millions) 2024 2023 Accounts receivable, net $ 377.2 $ 381.7 Deferred revenue $ 195.3 $ 138.2 c. Roche The Company is a party to a collaboration agreement with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV ® in the United States and Ronapreve ™ in other countries). Under the terms of the collaboration agreement, the Company has the right to distribute the product in the United States while Roche has the right to distribute the product outside the United States. The parties share gross profits from worldwide sales. Amounts recognized in the Company's Statements of Operations in connection with its Roche collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended (In millions) 2024 2023 2024 2023 Global gross profits earned in connection with sales of Ronapreve Collaboration revenue $ 0.5 $ — $ 1.4 $ 222.2 Other Collaboration revenue $ — $ (5.7) $ — $ (9.5) Contract balances in the Company's Balance Sheets in connection with the Roche collaboration were not material as of September 30, 2024 and December 31, 2023. d. Other In addition to the collaboration and license agreements discussed above, the Company has various other collaboration and license agreements that are not individually significant to its operating results or financial condition at this time. Pursuant to the terms of those agreements, the Company may be required to pay, or it may receive, additional amounts contingent upon the occurrence of various future events (e.g., upon the achievement of various development and commercial milestones), which in the aggregate could be significant. The Company may also incur, or get reimbursed for, significant research and development costs. During the three and nine months ended September 30, 2024, the Company recorded to Acquired in-process research and development expense a $45.0 million development milestone in connection with the Company's collaboration agreement with Sonoma Biotherapeutics, Inc. During the three and nine months ended September 30, 2023, the Company recorded to Acquired in-process research and development expense a $100.0 million development milestone in connection with the Company's collaboration agreement with Alnylam Pharmaceuticals, Inc. Acquired in-process research and development expense for the nine months ended September 30, 2023 also included a $45.0 million u p-front payment in connection with the Company's collaboration agreement with Sonoma.

Net Income Per Share

Net Income Per Share	9 Months Ended
Net Income Per Share	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In millions, except per share data) 2024 2023 2024 2023 Net income - basic and diluted $ 1,340.6 $ 1,007.8 $ 3,494.9 $ 2,794.0 Weighted average shares - basic 108.1 106.3 108.0 106.8 Effect of dilutive securities: Stock options 5.3 4.8 5.2 4.9 Restricted stock awards and restricted stock units 2.8 2.3 2.4 2.0 Weighted average shares - diluted 116.2 113.4 115.6 113.7 Net income per share - basic $ 12.40 $ 9.48 $ 32.36 $ 26.16 Net income per share - diluted $ 11.54 $ 8.89 $ 30.23 $ 24.57 Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: Three Months Ended September 30, Nine Months Ended September 30, (Shares in millions) 2024 2023 2024 2023 Stock options 0.1 1.7 1.5 1.7

Marketable Securities

Marketable Securities	9 Months Ended
Marketable Securities	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities Marketable securities as of September 30, 2024 and December 31, 2023 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6). The following tables summarize the Company's investments in available-for-sale debt securities: (In millions) Amortized Unrealized Fair As of September 30, 2024 Cost Basis Gains Losses Value Corporate bonds $ 7,708.2 $ 83.5 $ (24.4) $ 7,767.3 U.S. government and government agency obligations 5,985.8 14.1 (1.3) 5,998.6 Sovereign bonds 66.7 0.4 (0.2) 66.9 Commercial paper 556.6 1.0 — 557.6 Certificates of deposit 402.1 1.0 — 403.1 Asset-backed securities 173.2 0.8 (0.1) 173.9 $ 14,892.6 $ 100.8 $ (26.0) $ 14,967.4 As of December 31, 2023 Corporate bonds $ 6,492.5 $ 10.4 $ (104.9) $ 6,398.0 U.S. government and government agency obligations 4,839.6 2.4 (8.6) 4,833.4 Sovereign bonds 58.1 — (0.9) 57.2 Commercial paper 636.8 0.2 (0.2) 636.8 Certificates of deposit 520.8 0.6 — 521.4 Asset-backed securities 88.2 0.1 (1.2) 87.1 $ 12,636.0 $ 13.7 $ (115.8) $ 12,533.9 The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities as of September 30, 2024 mature at various dates through October 2029. The fair values of available-for-sale debt securities by contractual maturity consist of the following: September 30, December 31, (In millions) 2024 2023 Maturities within one year $ 7,784.7 $ 8,114.8 Maturities after one year through five years 7,181.9 4,414.5 Maturities after five years 0.8 4.6 $ 14,967.4 $ 12,533.9 The following table shows the fair value and gross unrealized losses by category and disaggregated by the length of time that the Company's available-for-sale debt securities have been in a continuous unrealized loss position. Less than 12 Months 12 Months or Greater Total (In millions) As of September 30, 2024 Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate bonds $ 6,351.7 $ (0.7) $ 1,415.6 $ (23.7) $ 7,767.3 $ (24.4) U.S. government and government agency obligations 5,799.9 (0.1) 198.7 (1.2) 5,998.6 (1.3) Sovereign bonds 46.0 — 20.9 (0.2) 66.9 (0.2) Asset-backed securities 141.6 — 32.3 (0.1) 173.9 (0.1) $ 12,339.2 $ (0.8) $ 1,667.5 $ (25.2) $ 14,006.7 $ (26.0) As of December 31, 2023 Corporate bonds $ 2,363.3 $ (2.4) $ 4,034.7 $ (102.5) $ 6,398.0 $ (104.9) U.S. government and government agency obligations 4,780.6 (6.0) 52.7 (2.6) 4,833.3 (8.6) Sovereign bonds 12.4 (0.1) 44.8 (0.8) 57.2 (0.9) Commercial paper 636.8 (0.2) — — 636.8 (0.2) Asset-backed securities 61.8 (0.3) 25.3 (0.9) 87.1 (1.2) $ 7,854.9 $ (9.0) $ 4,157.5 $ (106.8) $ 12,012.4 $ (115.8) The unrealized losses on corporate bonds were primarily driven by changes in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases. With respect to marketable securities, for the three and nine months ended September 30, 2024 and 2023, amounts reclassified from Accumulated other comprehensive income (loss) into Other income (expense), net were related to realized gains/losses on sales of available-for-sale debt securities. For the three and nine months ended September 30, 2024 and 2023, realized gains/losses on sales of marketable securities were not material.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The table below summarizes the Company's assets and liabilities which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets and liabilities, based on inputs to valuation techniques utilized to measure fair value: • Level 1 - Quoted prices in active markets for identical assets or liabilities • Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable • Level 3 - Significant other unobservable inputs (In millions) Fair Value Measurements at Reporting Date As of September 30, 2024 Fair Value Level 1 Level 2 Level 3 Assets: Cash equivalents $ 934.8 $ 517.3 $ 417.5 $ — Available-for-sale debt securities: Corporate bonds 7,767.3 — 7,767.3 — U.S. government and government agency obligations 5,998.6 — 5,998.6 — Sovereign bonds 66.9 — 66.9 — Commercial paper 557.6 — 557.6 — Certificates of deposit 403.1 — 403.1 — Asset-backed securities 173.9 — 173.9 — Equity securities (unrestricted) 1,232.1 1,232.1 — — Equity securities (restricted) (a) 76.1 76.1 — — Total assets $ 17,210.4 $ 1,825.5 $ 15,384.9 $ — Liabilities: Contingent consideration $ 36.7 $ — $ — $ 36.7 As of December 31, 2023 Assets: Cash equivalents $ 928.1 $ 6.4 $ 921.7 $ — Available-for-sale debt securities: Corporate bonds 6,398.0 — 6,398.0 — U.S. government and government agency obligations 4,833.4 — 4,833.4 — Sovereign bonds 57.2 — 57.2 — Commercial paper 636.8 — 636.8 — Certificates of deposit 521.4 — 521.4 — Asset-backed securities 87.1 — 87.1 — Equity securities (unrestricted) 864.5 864.5 — — Equity securities (restricted) 112.9 112.9 — — Total assets $ 14,439.4 $ 983.8 $ 13,455.6 $ — Liabilities: Contingent consideration $ 43.7 $ — $ — $ 43.7 (a) Includes equity securities which are subject to transfer restrictions that expire in April 2026 In addition to the investments summarized in the table above, as of September 30, 2024 and December 31, 2023, the Company had $159.8 million and $74.3 million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets. Also recorded within Other noncurrent assets as of September 30, 2024 were equity investments of $47.0 million which are measured at fair value based on Level 3 inputs; no such investments were held by the Company as of December 31, 2023. During the three and nine months ended September 30, 2024, the Company recorded $134.5 million and $330.8 million of net unrealized gains, respectively, on equity securities in Other income (expense), net; and during the three and nine months ended September 30, 2023, the Company recorded $100.3 million and $295.9 million of net unrealized losses, respectively, on equity securities in Other income (expense), net. In addition, during the three months ended September 30, 2023, the Company recorded a write-down of $29.0 million in Other income (expense), net related to the Company's investments in private companies. The fair value of the Company's long-term debt, which was determined based on Level 2 inputs, was estimated to be $1.577 billion and $1.528 billion as of September 30, 2024 and December 31, 2023, respectively.

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: September 30, December 31, (In millions) 2024 2023 Raw materials $ 856.6 $ 789.3 Work-in-process 1,230.1 1,121.8 Finished goods 164.6 147.3 Deferred costs 766.7 522.1 $ 3,018.0 $ 2,580.5 Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 10.2% and 9.3% for the three months ended September 30, 2024 and 2023, respectively, and 8.6% and 8.4% for the nine months ended September 30, 2024 and 2023, respectively. The Company's effective tax rate for the three and nine months ended September 30, 2024 was positively impacted, compared to the U.S. federal statutory rate, primarily by income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and stock-based compensation. The Company's effective tax rate for the nine months ended September 30, 2024 was negatively impacted by the remeasurement of existing uncertain tax positions. The Company's effective tax rate for the three and nine months ended September 30, 2023 was positively impacted, compared to the U.S. federal statutory rate, primarily by income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and, to a lesser extent, stock-based compensation and federal tax credits for research activities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity In January 2023, the Company's board of directors authorized a share repurchase program to repurchase up to $3.0 billion of the Company's Common Stock. As of September 30, 2024, the Company had repurchased the entire $3.0 billion of its Common Stock it was authorized to repurchase under the program. In April 2024, the Company's board of directors authorized a share repurchase program to repurchase up to an additional $3.0 billion of the Company's Common Stock. The share repurchase program permits the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. The table below summarizes the shares of the Company's Common Stock that the Company repurchased and the cost of such shares, which were recorded as Treasury Stock. Three Months Ended September 30, Nine Months Ended (In millions) 2024 2023 2024 2023 Number of shares 0.6 0.7 1.5 2.6 Total cost of shares $ 738.3 $ 507.1 $ 1,637.7 $ 1,923.8 As of September 30, 2024, $2.893 billion remained available for share repurchases under the April 2024 program.

Statement of Cash Flows

Statement of Cash Flows	9 Months Ended
Statement of Cash Flows	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Statement of Cash Flows	Statement of Cash Flows The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows: September 30, (In millions) 2024 2023 Cash and cash equivalents $ 2,011.8 $ 2,152.3 Restricted cash included in Other noncurrent assets — 7.9 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows $ 2,011.8 $ 2,160.2 Restricted cash consisted of amounts held by financial institutions pursuant to contractual arrangements. Supplemental disclosure of non-cash investing and financing activities September 30, December 31, September 30, December 31, (In millions) 2024 2023 2023 2022 Accrued capital expenditures $ 94.0 $ 75.4 $ 98.9 $ 70.8 Accrued contingent consideration in connection with acquisitions $ 88.0 $ 71.6 $ 106.5 $ 135.5

Legal Matters

Legal Matters	9 Months Ended
Legal Matters	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	Legal Matters From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company is unable to prevail in one or more of such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially adversely impacted. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September 30, 2024 and December 31, 2023, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. Proceedings Relating to Praluent (alirocumab) Injection United States On May 27, 2022, the Company filed a lawsuit against Amgen Inc. in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1 and 11, 2022, Amgen filed a motion to dismiss the complaint and a motion to stay these proceedings, respectively. On February 10, 2023, the court denied Amgen's motion to stay; and on March 21, 2023, the court denied Amgen's motion to dismiss. On August 28, 2023, the Company filed an amended complaint in this matter; and, as part of its response, on September 20, 2023, Amgen filed a counterclaim alleging that the Company engaged in unfair business practices in violation of state law. On May 22, 2024, Amgen filed a motion for summary judgment. An oral hearing on Amgen's motion for summary judgment has been scheduled for November 20, 2024. Europe On June 1, 2023, Sanofi filed an action in the Munich Central Division of the Unified Patent Court (the "UPC") seeking revocation of Amgen's European Patent No. 3,666,797 (the "'797 Patent"). The '797 Patent is a divisional patent of European Patent No. 2,215,124 (the "'124 Patent") (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent), which was previously invalidated by Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). A trial on the revocation action before the Munich Central Division of the UPC was held on June 4, 2024. On July 16, 2024, the Munich Central Division of the UPC issued a decision revoking the '797 Patent in its entirety. On September 16, 2024, Amgen appealed the decision of the Munich Central Division of the UPC to the Court of Appeal of the UPC. Also on June 1, 2023, Amgen filed a lawsuit against the Company and certain of Sanofi's affiliated entities in the Munich Local Division of the UPC alleging infringement of the '797 Patent. The lawsuit seeks, among other things, a permanent injunction in several countries in Europe and monetary damages. On July 29, 2024, the Munich Local Division of the UPC ordered a stay of the infringement lawsuit in light of the decision of the Munich Central Division of the UPC to revoke the '797 Patent in its entirety (discussed above). Proceedings Relating to EYLEA (aflibercept) Injection Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. United States Post-Grant Proceedings Before USPTO Company Patent(s) Challenger(s) Type of Challenge Date of Challenge Latest Events/Current Status U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") Mylan Pharmaceuticals Inc., joined by Apotex Inc. and Celltrion IPR petitions seeking declarations of invalidity May 5, 2021 On November 9, 2022, the USPTO issued final written decisions finding that the challenged claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of these decisions to the United States Court of Appeals for the Federal Circuit (the "Federal Circuit"). On July 9, 2024, the Company's appeal was voluntarily dismissed. U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") Mylan, joined by Celltrion ('601 and '681 Patents) and Samsung Bioepis Co., Ltd. ('601 Patent) IPR petitions seeking declarations of invalidity July 1, 2022 On January 9, 2024, the USPTO issued final written decisions finding that that the challenged claims of the '681 and '601 Patents are unpatentable and, therefore, invalid. On March 12, 2024, the Company filed notices of appeal of these decisions to the Federal Circuit. On August 20, 2024, the Company's appeal was voluntarily dismissed. Samsung Bioepis, joined by Biocon Biologics Inc. ('601 Patent) IPR petitions seeking declarations of invalidity January 6, 2023 ('681 Patent) March 26, 2023 ('601 Patent) On July 19, 2023 and October 20, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent, respectively. On June 14, 2024, the USPTO issued a final written decision finding that the challenged claims of the '681 Patent are unpatentable and, therefore, invalid. U.S. Patent No. 11,253,572 (the "'572 Patent") Samsung Bioepis IPR petition seeking declaration of invalidity April 27, 2023 On November 17, 2023, the USPTO instituted IPR proceedings concerning the '572 Patent. On July 11, 2024, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '572 Patent. U.S. Patent Litigation On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan, a wholly-owned subsidiary of Viatris Inc., in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for U.S. Food and Drug Administration ("FDA") approval of an aflibercept 2 mg biosimilar infringes certain Company patents. On April 20, 2023, Mylan filed a motion for summary judgment or partial summary judgment concerning four of the asserted patents. On April 26, 2023, the Company filed a stipulation accepting summary judgment of noninfringement of all asserted claims of the Company's U.S. Patent No. 11,104,715. On June 5, 2023, Biocon, as successor-in-interest to the aflibercept 2 mg biosimilar, was joined as a defendant to the lawsuit. A trial was held from June 12, 2023 through June 23, 2023 concerning certain claims of the '601 Patent, the '572 Patent, and the Company's U.S. Patent No. 11,084,865 (the "'865 Patent"). On December 27, 2023, the court issued a decision finding that (i) the asserted claims of the '865 Patent were valid and infringed by Mylan and Biocon and (ii) the asserted claims of the '601 and '572 Patents were infringed by Mylan and Biocon but were invalid as obvious. On June 11, 2024, the court granted the Company's motion for a permanent injunction, enjoining Mylan and Biocon from selling in the United States their aflibercept 2 mg biosimilar until the expiration of the '865 Patent. On June 21, 2024, Mylan and Biocon filed a notice of appeal of the court's December 27, 2023 and June 11, 2024 decisions to the Federal Circuit. On November 8, November 22, and November 29, 2023, respectively, the Company filed patent infringement lawsuits against Celltrion, Samsung Bioepis, and Formycon AG in the United States District Court for the Northern District of West Virginia following service on Regeneron of each company's notice of commercial marketing. The lawsuits allege that each company has infringed certain Company patents, including based on each company's filing for FDA approval of an aflibercept 2 mg biosimilar. On December 27, 2023, the Company filed a second patent infringement lawsuit against Samsung Bioepis in the United States District Court for the Northern District of West Virginia alleging that Samsung's filing for FDA approval of an aflibercept 2 mg biosimilar infringes certain Company patents. On June 14, June 21, and June 28, 2024, respectively, the court granted the Company's motions for preliminary injunctions against Samsung Bioepis, Formycon, and Celltrion. On June 14, June 25, and July 8, 2024, respectively, Samsung Bioepis, Formycon, and Celltrion filed notices of appeal of the court's preliminary injunction decisions to the Federal Circuit. An oral hearing concerning the respective notices of appeal of Samsung Bioepis and Formycon has been scheduled for December 5, 2024. On January 10, 2024, the Company filed a patent infringement lawsuit against Amgen in the United States District Court for the Central District of California alleging that Amgen's filing for FDA approval of an aflibercept 2 mg biosimilar infringes certain Company patents. On April 11, 2024, the United States Judicial Panel on Multidistrict Litigation granted the Company's motion to transfer this lawsuit to the United States District Court for the Northern District of West Virginia for coordinated and consolidated pretrial proceedings with the lawsuits described in the preceding paragraph. On June 7, 2024, the Company filed a motion for a preliminary injunction against Amgen. An oral hearing before the United States District Court for the Northern District of West Virginia was held on August 13, 2024. On September 23, 2024, the court denied the Company's motion for a preliminary injunction, and the Company filed (i) a notice of appeal of such decision to the Federal Circuit, (ii) a motion for an immediate administrative stay, and (iii) a motion for a temporary injunction preventing Amgen from launching its aflibercept 2 mg biosimilar during the pendency of such appeal. On September 25, 2024, the Federal Circuit issued an administrative stay pending its review of the Company's temporary injunction motion. On October 22, 2024, the Federal Circuit denied the Company's temporary injunction motion, lifted the administrative stay, and indicated that an expedited oral hearing on the Company's appeal to the Federal Circuit will be held in January 2025. On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringes certain Company patents. On September 12, 2024, the United States Judicial Panel on Multidistrict Litigation granted the Company's motion to transfer this lawsuit to the United States District Court for the Northern District of West Virginia for coordinated and consolidated pretrial proceedings with the lawsuits described in the preceding paragraphs. Europe Post-Grant Proceedings Authority/Court Company Patent(s) Challenger(s) Type of Challenge Date of Challenge Latest Events/Current Status EPO European Patent No. 2,944,306 (the "'306 Patent") Anonymous parties Opposition proceedings October 26 and October 27, 2021 Oral hearing scheduled for November 2024 EPO European Patent No. 3,716,992 (the "'992 Patent") Amgen and three anonymous parties Opposition proceedings May 5–10, 2023 Oral hearing to be scheduled EPO European Patent No. 3,384,049 (the "'049 Patent") Amgen and anonymous parties Opposition proceedings April 22–30, 2024 Oral hearing to be scheduled German Federal Patent Court German designation of European Patent No. 2,364,691 (the "'691 Patent") Samsung Bioepis NL B.V. Invalidation proceedings June 22, 2023 Trial has been scheduled to begin in June 2025 High Court of Justice of England and Wales United Kingdom designations of the '691 Patent and '306 Patent Formycon AG and Klinge Biopharma GmbH Invalidation proceedings and declaration of non-infringement by challengers' aflibercept 2 mg biosimilar April 18, 2024 Trial has been scheduled to begin in June 2025 Amgen Invalidation proceedings and declaration of non-infringement by challenger's aflibercept 2 mg biosimilar September 11, 2024 Trial has been scheduled to begin in June 2025 Samsung Bioepis UK Limited Invalidation proceedings and declaration of non-infringement by challenger's aflibercept 2 mg biosimilar October 2, 2024 Trial has been scheduled to begin in June 2025 High Court of Justice of England and Wales United Kingdom designation of the '992 Patent Amgen Invalidation proceedings May 13, 2024 Stayed pending final resolution of the '992 Patent EPO opposition proceedings listed above District Court of The Hague, the Netherlands Dutch designation of the '691 Patent and '306 Patent Samsung Bioepis NL B.V. Invalidation proceedings July 17, 2024 Trial for both patents has been scheduled for July 18, 2025 High Court of Justice of England and Wales United Kingdom designation of the '992 Patent Samsung Bioepis UK Limited Invalidation proceedings July 24, 2024 Stayed pending final resolution of the '992 Patent EPO opposition proceedings listed above Judicial Court of Paris French designation of the '691 Patent and '306 Patent Formycon AG Invalidation proceedings and declaration of non-infringement by challenger's aflibercept 2 mg biosimilar August 19, 2024 Trial to be scheduled Canada Proceedings against Amgen Canada On May 9, 2023, Amgen Canada Inc. ("Amgen Canada") filed invalidation proceedings against the Company in the Federal Court of Canada seeking revocation of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent") and 3,007,276 (the "'276 Patent"). On September 14, 2023, the Company, Bayer Inc., and Bayer Healthcare LLC filed patent infringement lawsuits against Amgen Canada in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar would directly or indirectly infringe one or more claims of Bayer Healthcare LLC's Canadian Patent No. 2,970,315 (the "'315 Patent"). On September 14, 2023, the Company and Bayer Inc. filed three separate patent infringement lawsuits against Amgen Canada in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 3,129,193 (the "'193 Patent"), 2,965,495 (the "'495 Patent"), and 2,906,768 (the "'768 Patent"), respectively. On October 11, 2023, the Company, Bayer Inc., and Bayer Healthcare LLC filed two separate patent infringement lawsuits against Amgen Canada in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar would directly or indirectly infringe one or more claims of the Company's '510 Patent and '276 Patent, respectively. On May 7, 2024 and June 28, 2024, respectively, Amgen filed a summary trial motion with respect to the '510 Patent and a motion to delist the '276 Patent from the Canada Patent Register. A hearing on the motion to delist the '276 Patent has been scheduled for November 2024. A trial for the lawsuits concerning the '510 Patent and the '276 Patent has been scheduled for May–June 2025; and a trial for the lawsuits concerning the '315 Patent and the '193 Patent has been scheduled for August–September 2025. Proceedings against Samsung On August 1, 2024, the Company, Bayer Inc., and Bayer Healthcare LLC filed patent infringement lawsuits against Samsung Bioepis Co., Ltd. in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar would directly or indirectly infringe one or more claims of the '510 Patent, the '276 Patent, the '495 Patent, the '768 Patent, the '193 Patent, the '315 Patent, and Canadian Patent No. 3,137,326 (the "'326 Patent"). On October 28, 2024, the Company, Bayer Inc., Bayer Healthcare LLC, and Samsung Bioepis Co., Ltd. entered into a settlement agreement concerning these patent infringement lawsuits, pursuant to which each such lawsuit will be dismissed and Samsung will generally be precluded from launching its aflibercept 2 mg biosimilar product in Canada until July 1, 2025. South Korea On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811 (the "'811 Patent"), respectively, seeking revocation of each such patent in its entirety. Set forth below is a summary of patent infringement lawsuits filed by the Company and, as applicable, Bayer Consumer Care AG before the Seoul Central District Court based on allegations that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar by the relevant defendant(s) would infringe one or more claims of the Company's patents listed below. Company Patent(s) Defendant(s) Relief Sought Date of Action Korean Patent No. 659477 (the "'477 Patent") Samsung Bioepis Co., Ltd. and its parent company Samsung Biologics Co., Ltd. Damages January 16, 2023 Sam Chun Dang Pharm. Co., Ltd. and OPTUS Pharmaceutical Co., Ltd Damages January 8, 2024 '477 Patent, '811 Patent, and Korean Patent No. 2519234 (the "'234 Patent") Celltrion Inc. Damages and injunctive relief January 10, 2024 '811 Patent and '234 Patent Sam Chun Dang Pharm. Co., Ltd. and OPTUS Pharmaceutical Co., Ltd Damages and injunctive relief May 8, 2024 Samsung Bioepis Co., Ltd., its parent company Samsung Biologics Co., Ltd., and Samil Pharmaceuticals Co., Ltd Injunctive relief May 14, 2024 '811 Patent Samsung Bioepis Co., Ltd., its parent company Samsung Biologics Co., Ltd., and Samil Pharmaceuticals Co., Ltd. Injunctive relief July 30, 2024 Celltrion Inc. and Kukje Pharmaceuticals, Inc. Injunctive relief July 30, 2024 Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of Novartis's U.S. Patent No. 9,220,631 (the "'631 Patent") and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below. On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. An oral hearing was held on August 6, 2024. On September 23, 2024, the Federal Circuit affirmed the PTAB's decision invalidating all claims of the '631 Patent. On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the lawsuit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On January 31, 2022, the court granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit (the "Second Circuit"). On March 18, 2024, the Second Circuit reversed the District Court's decision to dismiss the amended complaint and remanded the lawsuit to the District Court for further proceedings consistent with the Second Circuit's opinion. Proceedings Relating to REGEN-COV (casirivimab and imdevimab) On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent"). Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022. On September 18, 2023, the parties entered into a stipulation that narrowed the case to (i) whether any safe harbor defense under federal law applies to Regeneron's use of the invention covered, based on the court's claim construction, by the '221 Patent; (ii) damages for any use by Regeneron found to not be covered by such safe harbor defense; and (iii) whether any use referred to in clause (ii) above was willful. On October 4, 2024, the court granted Allele's motion for summary judgment and found that the safe harbor defense under federal law does not apply to Regeneron's use of the invention covered, based on the court's claim construction, by the '221 Patent. A trial date has not yet been scheduled. Department of Justice Matters In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST ® , and ZALTRAP ® ); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law (the "June 2020 Civil Complaint"). On August 24, 2020, the Company filed a motion to dismiss the June 2020 Civil Complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney's Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment. An oral hearing on the parties' respective motions for summary judgment was held on July 21, 2023. On September 27, 2023, the court (i) denied in part and granted in part the Company's motion for summary judgment and (ii) denied in its entirety the motion for partial summary judgment filed by the U.S. Attorney's Office for the District of Massachusetts. On October 25, 2023, the court certified for interlocutory appeal a portion of the court's September 27, 2023 order that addressed the causation standard applicable to the alleged violations of the federal Anti-Kickback Statute and federal False Claims Act; and on December 11, 2023, the U.S. Court of Appeals for the First Circuit certified for appeal (i.e., accepted for review) the court's September 27, 2023 order. An oral hearing concerning the appeal to the U.S. Court of Appeals for the First Circuit was held on July 22, 2024. In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a qui tam complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two qui tam plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the qui tam plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety. On July 25, 2023, the court granted in part and denied in part the Company's motion to dismiss. On September 1, 2023, the Company filed a second motion to dismiss the amended complaint or, in the alternative, a motion for judgment on the pleadings. On July 31, 2024 and August 15, 2024, respectively, the District Court granted the Company's second motion to dismiss the amended complaint with respect to the remaining causes of action under federal law and declined to exercise supplemental jurisdiction over the remaining causes of action under state law. On August 26, 2024, the qui tam plaintiffs filed a notice of appeal. In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to the Centers for Medicare & Medicaid Services. The CID covers the period from January 2011 through June 2021. On November 29, 2023, the U.S. Department of Justice informed the Company that it had filed a notice of partial intervention in this matter. On March 28, 2024, the Department of Justice and the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint intervention (the "March 2024 Civil Complaint") in the U.S. District Court for the District of Massachusetts asserting causes of action under the federal False Claims Act and a claim for unjust enrichment. Also on March 28, 2024, the U.S. District Court of the District of Massachusetts unsealed a qui tam complaint against the Company, AmerisourceBergen, and Besse Medical by two qui tam plaintiffs (known as relators) purportedly on behalf of the United States and various states and municipalities, asserting causes of action under the federal False Claims Act and state and local laws, and alleging violations of the federal Anti-Kickback statute. On June 25, 2024, the States of Colorado, Georgia, Michigan, North Carolina, Texas, and Washington filed a civil complaint in partial intervention (the "June 2024 Civil Complaint") in the U.S. District Court for the District of Massachusetts asserting causes of action under various state laws. On July 18, 2024, the Company filed a motion to dismiss the March 2024 Civil Complaint and the June 2024 Civil Complaint. An oral hearing has been scheduled for December 16, 2024. California Department of Insurance Subpoena In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation. Proceedings Initiated by Other Payors The Company is party to several lawsuits relating to the conduct alleged in the June 2020 Civil Complaint discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. (collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act ("RICO") and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts concerning the allegations in the June 2020 Civil Complaint. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court concerning the allegations in the June 2020 Civil Complaint; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter. On June 24, 2024, a group of plaintiffs purporting to be assignees of claims by various Medicare Advantage plans and related entities filed a putative class action complaint in the U.S. District Court for the District of Columbia on behalf of Medicare Advantage plans and other payors. The lawsuit relates to the conduct alleged in the June 2020 Civil Complaint, March 2024 Civil Complaint, and June 2024 Civil Complaint discussed under "Department of Justice Matters" above. The lawsuit alleges causes of action under state law and RICO a

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income	$ 1,340.6	$ 1,432.3	$ 722	$ 1,007.8	$ 968.4	$ 817.8	$ 3,494.9	$ 2,794

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		As disclosed in the table below, during the three months ended September 30, 2024, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (a) Total Number of Securities to Be Sold Under the Plan Joseph L. Goldstein, M.D. Director 8/7/2024 2/7/2025 1,929 Jason Pitofsky Vice President, Controller 8/7/2024 5/10/2025 3,791 Arthur F. Ryan Director 8/3/2024 10/31/2025 1,200 (a) In each case, the trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Joseph L. Goldstein, M.D. [Member]
Trading Arrangements, by Individual
Name	Joseph L. Goldstein, M.D.
Title	Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	8/7/2024
Expiration Date	2/7/2025
Arrangement Duration	184 days
Aggregate Available	1,929	1,929
Jason Pitofsky [Member]
Trading Arrangements, by Individual
Name	Jason Pitofsky
Title	Vice President, Controller
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	8/7/2024
Expiration Date	5/10/2025
Arrangement Duration	276 days
Aggregate Available	3,791	3,791
Arthur F. Ryan [Member]
Trading Arrangements, by Individual
Name	Arthur F. Ryan
Title	Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	8/3/2024
Expiration Date	10/31/2025
Arrangement Duration	454 days
Aggregate Available	1,200	1,200

Interim Financial Statements (P

Interim Financial Statements (Policies)	9 Months Ended
Interim Financial Statements (Policies)	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December 31, 2023 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Recently Issued Accounting Standards	In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures . The amendments require disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in Accounting Standards Codification 280, Segment Reporting . The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements. In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures . The amendments require (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.
Legal Matters	Costs associated with the Company's involvement in legal proceedings are expensed as incurred.

Product Sales (Tables)

Product Sales (Tables)	9 Months Ended
Product Sales (Tables)	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Product Sales	Net product sales consist of the following: Three Months Ended Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 EYLEA HD ® U.S. $ 392.3 $ 42.7 $ 896.5 $ 42.7 EYLEA ® U.S. 1,144.6 1,448.2 3,576.7 4,382.1 Total EYLEA HD and EYLEA U.S. 1,536.9 1,490.9 4,473.2 4,424.8 Libtayo ® U.S. 194.5 144.1 536.1 384.0 Libtayo Rest of world 94.1 88.3 313.8 235.3 Total Libtayo Global 288.6 232.4 849.9 619.3 Praluent ® U.S. 52.9 40.4 179.0 121.1 Evkeeza ® U.S. 32.4 19.1 87.6 53.3 Inmazeb ® Global 35.6 3.3 36.6 7.7 $ 1,946.4 $ 1,786.1 $ 5,626.3 $ 5,226.2 Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Regeneron's share of profits Collaboration revenue $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Sales-based milestones earned Collaboration revenue $ — $ 50.0 $ — $ 50.0 Reimbursement for manufacturing of commercial supplies Collaboration revenue $ 175.1 $ 151.5 $ 438.2 $ 506.0 Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses (R&D expense) $ (7.8) $ (25.8) $ (35.5) $ (66.7) Reimbursement of commercialization-related expenses Reduction of SG&A expense $ 169.0 $ 135.5 $ 459.3 $ 384.0 Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Regeneron's share of profits Collaboration revenue $ 367.6 $ 349.9 $ 1,054.5 $ 1,031.0 Reimbursement for manufacturing of ex-U.S. commercial supplies Collaboration revenue $ 23.2 $ 27.2 $ 67.4 $ 79.7 Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses (R&D expense) $ (11.8) $ (9.7) $ (35.2) $ (35.1) Amounts recognized in the Company's Statements of Operations in connection with its Roche collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended (In millions) 2024 2023 2024 2023 Global gross profits earned in connection with sales of Ronapreve Collaboration revenue $ 0.5 $ — $ 1.4 $ 222.2 Other Collaboration revenue $ — $ (5.7) $ — $ (9.5)
Schedules of Sales to Customers as Percentage of Total Gross Product Revenue	Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows: Three Months Ended September 30, Nine Months Ended 2024 2023 2024 2023 Besse Medical, a subsidiary of Cencora, Inc. 51 % 53 % 51 % 52 % McKesson Corporation 24 % 24 % 24 % 25 %

Collaboration, License, and O_2

Collaboration, License, and Other Agreements (Tables)	9 Months Ended
Collaboration, License, and Other Agreements (Tables)	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Collaborative Revenue	Net product sales consist of the following: Three Months Ended Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 EYLEA HD ® U.S. $ 392.3 $ 42.7 $ 896.5 $ 42.7 EYLEA ® U.S. 1,144.6 1,448.2 3,576.7 4,382.1 Total EYLEA HD and EYLEA U.S. 1,536.9 1,490.9 4,473.2 4,424.8 Libtayo ® U.S. 194.5 144.1 536.1 384.0 Libtayo Rest of world 94.1 88.3 313.8 235.3 Total Libtayo Global 288.6 232.4 849.9 619.3 Praluent ® U.S. 52.9 40.4 179.0 121.1 Evkeeza ® U.S. 32.4 19.1 87.6 53.3 Inmazeb ® Global 35.6 3.3 36.6 7.7 $ 1,946.4 $ 1,786.1 $ 5,626.3 $ 5,226.2 Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Regeneron's share of profits Collaboration revenue $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Sales-based milestones earned Collaboration revenue $ — $ 50.0 $ — $ 50.0 Reimbursement for manufacturing of commercial supplies Collaboration revenue $ 175.1 $ 151.5 $ 438.2 $ 506.0 Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses (R&D expense) $ (7.8) $ (25.8) $ (35.5) $ (66.7) Reimbursement of commercialization-related expenses Reduction of SG&A expense $ 169.0 $ 135.5 $ 459.3 $ 384.0 Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Regeneron's share of profits Collaboration revenue $ 367.6 $ 349.9 $ 1,054.5 $ 1,031.0 Reimbursement for manufacturing of ex-U.S. commercial supplies Collaboration revenue $ 23.2 $ 27.2 $ 67.4 $ 79.7 Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses (R&D expense) $ (11.8) $ (9.7) $ (35.2) $ (35.1) Amounts recognized in the Company's Statements of Operations in connection with its Roche collaboration are as follows: Statement of Operations Classification Three Months Ended September 30, Nine Months Ended (In millions) 2024 2023 2024 2023 Global gross profits earned in connection with sales of Ronapreve Collaboration revenue $ 0.5 $ — $ 1.4 $ 222.2 Other Collaboration revenue $ — $ (5.7) $ — $ (9.5)
Schedule of Accounts Receivable and Deferred Revenue Information	The following table summarizes contract balances in connection with the Company's Sanofi collaboration: September 30, December 31, (In millions) 2024 2023 Accounts receivable, net $ 1,270.5 $ 1,029.1 Deferred revenue $ 621.4 $ 427.7 The following table summarizes contract balances in connection with the Company's Bayer collaboration: September 30, December 31, (In millions) 2024 2023 Accounts receivable, net $ 377.2 $ 381.7 Deferred revenue $ 195.3 $ 138.2

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
Net Income Per Share (Tables)	Sep. 30, 2024
Earnings Per Share [Abstract]
Basic and Diluted Net Income (Loss) Per Share	The calculations of basic and diluted net income per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In millions, except per share data) 2024 2023 2024 2023 Net income - basic and diluted $ 1,340.6 $ 1,007.8 $ 3,494.9 $ 2,794.0 Weighted average shares - basic 108.1 106.3 108.0 106.8 Effect of dilutive securities: Stock options 5.3 4.8 5.2 4.9 Restricted stock awards and restricted stock units 2.8 2.3 2.4 2.0 Weighted average shares - diluted 116.2 113.4 115.6 113.7 Net income per share - basic $ 12.40 $ 9.48 $ 32.36 $ 26.16 Net income per share - diluted $ 11.54 $ 8.89 $ 30.23 $ 24.57
Antidilutive Securities	Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: Three Months Ended September 30, Nine Months Ended September 30, (Shares in millions) 2024 2023 2024 2023 Stock options 0.1 1.7 1.5 1.7

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
Marketable Securities (Tables)	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Debt Securities	The following tables summarize the Company's investments in available-for-sale debt securities: (In millions) Amortized Unrealized Fair As of September 30, 2024 Cost Basis Gains Losses Value Corporate bonds $ 7,708.2 $ 83.5 $ (24.4) $ 7,767.3 U.S. government and government agency obligations 5,985.8 14.1 (1.3) 5,998.6 Sovereign bonds 66.7 0.4 (0.2) 66.9 Commercial paper 556.6 1.0 — 557.6 Certificates of deposit 402.1 1.0 — 403.1 Asset-backed securities 173.2 0.8 (0.1) 173.9 $ 14,892.6 $ 100.8 $ (26.0) $ 14,967.4 As of December 31, 2023 Corporate bonds $ 6,492.5 $ 10.4 $ (104.9) $ 6,398.0 U.S. government and government agency obligations 4,839.6 2.4 (8.6) 4,833.4 Sovereign bonds 58.1 — (0.9) 57.2 Commercial paper 636.8 0.2 (0.2) 636.8 Certificates of deposit 520.8 0.6 — 521.4 Asset-backed securities 88.2 0.1 (1.2) 87.1 $ 12,636.0 $ 13.7 $ (115.8) $ 12,533.9
Marketable Securities, Based on Contractual Maturity Dates	The fair values of available-for-sale debt securities by contractual maturity consist of the following: September 30, December 31, (In millions) 2024 2023 Maturities within one year $ 7,784.7 $ 8,114.8 Maturities after one year through five years 7,181.9 4,414.5 Maturities after five years 0.8 4.6 $ 14,967.4 $ 12,533.9
Fair Value and Unrealized Losses of Marketable Securities	The following table shows the fair value and gross unrealized losses by category and disaggregated by the length of time that the Company's available-for-sale debt securities have been in a continuous unrealized loss position. Less than 12 Months 12 Months or Greater Total (In millions) As of September 30, 2024 Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate bonds $ 6,351.7 $ (0.7) $ 1,415.6 $ (23.7) $ 7,767.3 $ (24.4) U.S. government and government agency obligations 5,799.9 (0.1) 198.7 (1.2) 5,998.6 (1.3) Sovereign bonds 46.0 — 20.9 (0.2) 66.9 (0.2) Asset-backed securities 141.6 — 32.3 (0.1) 173.9 (0.1) $ 12,339.2 $ (0.8) $ 1,667.5 $ (25.2) $ 14,006.7 $ (26.0) As of December 31, 2023 Corporate bonds $ 2,363.3 $ (2.4) $ 4,034.7 $ (102.5) $ 6,398.0 $ (104.9) U.S. government and government agency obligations 4,780.6 (6.0) 52.7 (2.6) 4,833.3 (8.6) Sovereign bonds 12.4 (0.1) 44.8 (0.8) 57.2 (0.9) Commercial paper 636.8 (0.2) — — 636.8 (0.2) Asset-backed securities 61.8 (0.3) 25.3 (0.9) 87.1 (1.2) $ 7,854.9 $ (9.0) $ 4,157.5 $ (106.8) $ 12,012.4 $ (115.8)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value On a Recurring Basis	The table below summarizes the Company's assets and liabilities which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets and liabilities, based on inputs to valuation techniques utilized to measure fair value: • Level 1 - Quoted prices in active markets for identical assets or liabilities • Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable • Level 3 - Significant other unobservable inputs (In millions) Fair Value Measurements at Reporting Date As of September 30, 2024 Fair Value Level 1 Level 2 Level 3 Assets: Cash equivalents $ 934.8 $ 517.3 $ 417.5 $ — Available-for-sale debt securities: Corporate bonds 7,767.3 — 7,767.3 — U.S. government and government agency obligations 5,998.6 — 5,998.6 — Sovereign bonds 66.9 — 66.9 — Commercial paper 557.6 — 557.6 — Certificates of deposit 403.1 — 403.1 — Asset-backed securities 173.9 — 173.9 — Equity securities (unrestricted) 1,232.1 1,232.1 — — Equity securities (restricted) (a) 76.1 76.1 — — Total assets $ 17,210.4 $ 1,825.5 $ 15,384.9 $ — Liabilities: Contingent consideration $ 36.7 $ — $ — $ 36.7 As of December 31, 2023 Assets: Cash equivalents $ 928.1 $ 6.4 $ 921.7 $ — Available-for-sale debt securities: Corporate bonds 6,398.0 — 6,398.0 — U.S. government and government agency obligations 4,833.4 — 4,833.4 — Sovereign bonds 57.2 — 57.2 — Commercial paper 636.8 — 636.8 — Certificates of deposit 521.4 — 521.4 — Asset-backed securities 87.1 — 87.1 — Equity securities (unrestricted) 864.5 864.5 — — Equity securities (restricted) 112.9 112.9 — — Total assets $ 14,439.4 $ 983.8 $ 13,455.6 $ — Liabilities: Contingent consideration $ 43.7 $ — $ — $ 43.7 (a) Includes equity securities which are subject to transfer restrictions that expire in April 2026

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: September 30, December 31, (In millions) 2024 2023 Raw materials $ 856.6 $ 789.3 Work-in-process 1,230.1 1,121.8 Finished goods 164.6 147.3 Deferred costs 766.7 522.1 $ 3,018.0 $ 2,580.5

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2024
Equity [Abstract]
Schedule of Shares Repurchased	The table below summarizes the shares of the Company's Common Stock that the Company repurchased and the cost of such shares, which were recorded as Treasury Stock. Three Months Ended September 30, Nine Months Ended (In millions) 2024 2023 2024 2023 Number of shares 0.6 0.7 1.5 2.6 Total cost of shares $ 738.3 $ 507.1 $ 1,637.7 $ 1,923.8

Statement of Cash Flows (Tables

Statement of Cash Flows (Tables)	9 Months Ended
Statement of Cash Flows (Tables)	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows: September 30, (In millions) 2024 2023 Cash and cash equivalents $ 2,011.8 $ 2,152.3 Restricted cash included in Other noncurrent assets — 7.9 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows $ 2,011.8 $ 2,160.2
Restrictions on Cash and Cash Equivalents	The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows: September 30, (In millions) 2024 2023 Cash and cash equivalents $ 2,011.8 $ 2,152.3 Restricted cash included in Other noncurrent assets — 7.9 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows $ 2,011.8 $ 2,160.2
Summary of Non-Cash Investing and Financing Activities	September 30, December 31, September 30, December 31, (In millions) 2024 2023 2023 2022 Accrued capital expenditures $ 94.0 $ 75.4 $ 98.9 $ 70.8 Accrued contingent consideration in connection with acquisitions $ 88.0 $ 71.6 $ 106.5 $ 135.5

Legal Matters (Tables)

Legal Matters (Tables)	9 Months Ended
Legal Matters (Tables)	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency	Post-Grant Proceedings Before USPTO Company Patent(s) Challenger(s) Type of Challenge Date of Challenge Latest Events/Current Status U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") Mylan Pharmaceuticals Inc., joined by Apotex Inc. and Celltrion IPR petitions seeking declarations of invalidity May 5, 2021 On November 9, 2022, the USPTO issued final written decisions finding that the challenged claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of these decisions to the United States Court of Appeals for the Federal Circuit (the "Federal Circuit"). On July 9, 2024, the Company's appeal was voluntarily dismissed. U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") Mylan, joined by Celltrion ('601 and '681 Patents) and Samsung Bioepis Co., Ltd. ('601 Patent) IPR petitions seeking declarations of invalidity July 1, 2022 On January 9, 2024, the USPTO issued final written decisions finding that that the challenged claims of the '681 and '601 Patents are unpatentable and, therefore, invalid. On March 12, 2024, the Company filed notices of appeal of these decisions to the Federal Circuit. On August 20, 2024, the Company's appeal was voluntarily dismissed. Samsung Bioepis, joined by Biocon Biologics Inc. ('601 Patent) IPR petitions seeking declarations of invalidity January 6, 2023 ('681 Patent) March 26, 2023 ('601 Patent) On July 19, 2023 and October 20, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent, respectively. On June 14, 2024, the USPTO issued a final written decision finding that the challenged claims of the '681 Patent are unpatentable and, therefore, invalid. U.S. Patent No. 11,253,572 (the "'572 Patent") Samsung Bioepis IPR petition seeking declaration of invalidity April 27, 2023 On November 17, 2023, the USPTO instituted IPR proceedings concerning the '572 Patent. On July 11, 2024, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '572 Patent. Post-Grant Proceedings Authority/Court Company Patent(s) Challenger(s) Type of Challenge Date of Challenge Latest Events/Current Status EPO European Patent No. 2,944,306 (the "'306 Patent") Anonymous parties Opposition proceedings October 26 and October 27, 2021 Oral hearing scheduled for November 2024 EPO European Patent No. 3,716,992 (the "'992 Patent") Amgen and three anonymous parties Opposition proceedings May 5–10, 2023 Oral hearing to be scheduled EPO European Patent No. 3,384,049 (the "'049 Patent") Amgen and anonymous parties Opposition proceedings April 22–30, 2024 Oral hearing to be scheduled German Federal Patent Court German designation of European Patent No. 2,364,691 (the "'691 Patent") Samsung Bioepis NL B.V. Invalidation proceedings June 22, 2023 Trial has been scheduled to begin in June 2025 High Court of Justice of England and Wales United Kingdom designations of the '691 Patent and '306 Patent Formycon AG and Klinge Biopharma GmbH Invalidation proceedings and declaration of non-infringement by challengers' aflibercept 2 mg biosimilar April 18, 2024 Trial has been scheduled to begin in June 2025 Amgen Invalidation proceedings and declaration of non-infringement by challenger's aflibercept 2 mg biosimilar September 11, 2024 Trial has been scheduled to begin in June 2025 Samsung Bioepis UK Limited Invalidation proceedings and declaration of non-infringement by challenger's aflibercept 2 mg biosimilar October 2, 2024 Trial has been scheduled to begin in June 2025 High Court of Justice of England and Wales United Kingdom designation of the '992 Patent Amgen Invalidation proceedings May 13, 2024 Stayed pending final resolution of the '992 Patent EPO opposition proceedings listed above District Court of The Hague, the Netherlands Dutch designation of the '691 Patent and '306 Patent Samsung Bioepis NL B.V. Invalidation proceedings July 17, 2024 Trial for both patents has been scheduled for July 18, 2025 High Court of Justice of England and Wales United Kingdom designation of the '992 Patent Samsung Bioepis UK Limited Invalidation proceedings July 24, 2024 Stayed pending final resolution of the '992 Patent EPO opposition proceedings listed above Judicial Court of Paris French designation of the '691 Patent and '306 Patent Formycon AG Invalidation proceedings and declaration of non-infringement by challenger's aflibercept 2 mg biosimilar August 19, 2024 Trial to be scheduled Set forth below is a summary of patent infringement lawsuits filed by the Company and, as applicable, Bayer Consumer Care AG before the Seoul Central District Court based on allegations that the making, constructing, using, or selling of an aflibercept 2 mg biosimilar by the relevant defendant(s) would infringe one or more claims of the Company's patents listed below. Company Patent(s) Defendant(s) Relief Sought Date of Action Korean Patent No. 659477 (the "'477 Patent") Samsung Bioepis Co., Ltd. and its parent company Samsung Biologics Co., Ltd. Damages January 16, 2023 Sam Chun Dang Pharm. Co., Ltd. and OPTUS Pharmaceutical Co., Ltd Damages January 8, 2024 '477 Patent, '811 Patent, and Korean Patent No. 2519234 (the "'234 Patent") Celltrion Inc. Damages and injunctive relief January 10, 2024 '811 Patent and '234 Patent Sam Chun Dang Pharm. Co., Ltd. and OPTUS Pharmaceutical Co., Ltd Damages and injunctive relief May 8, 2024 Samsung Bioepis Co., Ltd., its parent company Samsung Biologics Co., Ltd., and Samil Pharmaceuticals Co., Ltd Injunctive relief May 14, 2024 '811 Patent Samsung Bioepis Co., Ltd., its parent company Samsung Biologics Co., Ltd., and Samil Pharmaceuticals Co., Ltd. Injunctive relief July 30, 2024 Celltrion Inc. and Kukje Pharmaceuticals, Inc. Injunctive relief July 30, 2024

Product Sales - Schedule of Net

Product Sales - Schedule of Net Product Sales (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 3,720.7	$ 3,362.7	$ 10,412.8	$ 9,682.9
Net product sales
Disaggregation of Revenue [Line Items]
Revenues	1,946.4	1,786.1	5,626.3	5,226.2
Libtayo
Disaggregation of Revenue [Line Items]
Revenues	288.6	232.4	849.9	619.3
Inmazeb
Disaggregation of Revenue [Line Items]
Revenues	35.6	3.3	36.6	7.7
U.S. \| ELYEA HD And EYLEA
Disaggregation of Revenue [Line Items]
Revenues	1,536.9	1,490.9	4,473.2	4,424.8
U.S. \| ELYEA HD
Disaggregation of Revenue [Line Items]
Revenues	392.3	42.7	896.5	42.7
U.S. \| EYLEA
Disaggregation of Revenue [Line Items]
Revenues	1,144.6	1,448.2	3,576.7	4,382.1
U.S. \| Libtayo
Disaggregation of Revenue [Line Items]
Revenues	194.5	144.1	536.1	384
U.S. \| Praluent
Disaggregation of Revenue [Line Items]
Revenues	52.9	40.4	179	121.1
U.S. \| Evkeeza
Disaggregation of Revenue [Line Items]
Revenues	32.4	19.1	87.6	53.3
Rest Of World \| Libtayo
Disaggregation of Revenue [Line Items]
Revenues	$ 94.1	$ 88.3	$ 313.8	$ 235.3

Product Sales - Narrative (Deta

Product Sales - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 6,107.1	$ 5,667.3
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 4,142	$ 3,888

Product Sales - Schedule of Con

Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details) - Gross product revenue - Customer concentration risk	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Besse Medical, a subsidiary of Cencora, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage	51%	53%	51%	52%
McKesson Corporation
Concentration Risk [Line Items]
Concentration risk, percentage	24%	24%	24%	25%

Collaboration, License, and O_3

Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - Sanofi Collaboration Agreement, Antibody - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Percentage share of profits to reimburse collaborating party		20%
Contingent reimbursement obligation		$ 1,810
Sales Milestone Five
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, variable consideration amount	$ 50
Levels of twelve month sales at which sales milestone payments would be received	$ 3,000
Period for achieving sales target for milestone payment, rolling basis	12 months
Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party		80%
Percentage share of profits to reimburse collaborating party		30%
Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party		100%
Percentage share of profits to reimburse collaborating party		50%

Collaboration, License, and O_4

Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 3,720.7	$ 3,362.7	$ 10,412.8	$ 9,682.9
Sanofi Collaboration Agreement, Antibody \| Collaboration revenue \| Regeneron's share of profits
Disaggregation of Revenue [Line Items]
Revenues	1,088.3	863	2,880.6	2,250.6
Sanofi Collaboration Agreement, Antibody \| Collaboration revenue \| Sales-based milestones earned
Disaggregation of Revenue [Line Items]
Revenues	0	50	0	50
Sanofi Collaboration Agreement, Antibody \| Collaboration revenue \| Reimbursement for manufacturing of commercial supplies
Disaggregation of Revenue [Line Items]
Revenues	175.1	151.5	438.2	506
Sanofi Collaboration Agreement, Antibody \| (R&D expense) \| Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses
Disaggregation of Revenue [Line Items]
Revenues	(7.8)	(25.8)	(35.5)	(66.7)
Sanofi Collaboration Agreement, Antibody \| Reduction of SG&A expense \| Reimbursement of commercialization-related expenses
Disaggregation of Revenue [Line Items]
Revenues	$ 169	$ 135.5	$ 459.3	$ 384

Collaboration, License, and O_5

Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Accounts receivable, net	$ 6,107.1	$ 5,667.3
Sanofi Collaboration Agreement, Antibody
Disaggregation of Revenue [Line Items]
Accounts receivable, net	1,270.5	1,029.1
Deferred revenue	$ 621.4	$ 427.7

Collaboration, License, and O_6

Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 3,720.7	$ 3,362.7	$ 10,412.8	$ 9,682.9
Bayer \| Rest Of World \| Collaboration revenue \| Regeneron's share of profits
Disaggregation of Revenue [Line Items]
Revenues	367.6	349.9	1,054.5	1,031
Bayer \| Rest Of World \| Collaboration revenue \| Reimbursement for manufacturing of ex-U.S. commercial supplies
Disaggregation of Revenue [Line Items]
Revenues	23.2	27.2	67.4	79.7
Bayer \| Rest Of World \| (R&D expense) \| Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses
Disaggregation of Revenue [Line Items]
Revenues	$ (11.8)	$ (9.7)	$ (35.2)	$ (35.1)

Collaboration, License, and O_7

Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Accounts receivable, net	$ 6,107.1	$ 5,667.3
Bayer
Disaggregation of Revenue [Line Items]
Accounts receivable, net	377.2	381.7
Deferred revenue	$ 195.3	$ 138.2

Collaboration, License, and O_8

Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 3,720.7	$ 3,362.7	$ 10,412.8	$ 9,682.9
Ronapreve \| Roche Collaboration Agreement \| Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues	0.5	0	1.4	222.2
Other \| Roche Collaboration Agreement \| Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues	$ 0	$ (5.7)	$ 0	$ (9.5)

Collaboration, License, and O_9

Collaboration, License, and Other Agreements - Other Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Acquired in-process research and development	$ 56.2	$ 100	$ 87.2	$ 156.1
Sonoma Biotherapeutics, Inc.
Disaggregation of Revenue [Line Items]
Acquired in-process research and development	$ 45		$ 45	45
Alnylam Pharmaceuticals, Inc
Disaggregation of Revenue [Line Items]
Acquired in-process research and development		$ 100		$ 100

Net Income Per Share - Schedule

Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net income - basic and diluted	$ 1,340.6	$ 1,432.3	$ 722	$ 1,007.8	$ 968.4	$ 817.8	$ 3,494.9	$ 2,794
Weighted average shares - basic (in shares)	108.1			106.3			108	106.8
Weighted average shares - diluted (in shares)	116.2			113.4			115.6	113.7
Net income per share - basic (in dollars per share)	$ 12.40			$ 9.48			$ 32.36	$ 26.16
Net income per share - diluted (in dollars per share)	$ 11.54			$ 8.89			$ 30.23	$ 24.57
Stock options
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Effect of dilutive securities (in shares)	5.3			4.8			5.2	4.9
Restricted stock awards and restricted stock units
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Effect of dilutive securities (in shares)	2.8			2.3			2.4	2

Net Income Per Share - Schedu_2

Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options (in shares)	0.1	1.7	1.5	1.7

Marketable Securities - Schedul

Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	$ 14,892.6	$ 12,636
Unrealized Gains	100.8	13.7
Unrealized Losses	(26)	(115.8)
Fair Value	14,967.4	12,533.9
Corporate bonds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	7,708.2	6,492.5
Unrealized Gains	83.5	10.4
Unrealized Losses	(24.4)	(104.9)
Fair Value	7,767.3	6,398
U.S. government and government agency obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	5,985.8	4,839.6
Unrealized Gains	14.1	2.4
Unrealized Losses	(1.3)	(8.6)
Fair Value	5,998.6	4,833.4
Sovereign bonds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	66.7	58.1
Unrealized Gains	0.4	0
Unrealized Losses	(0.2)	(0.9)
Fair Value	66.9	57.2
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	556.6	636.8
Unrealized Gains	1	0.2
Unrealized Losses	0	(0.2)
Fair Value	557.6	636.8
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	402.1	520.8
Unrealized Gains	1	0.6
Unrealized Losses	0	0
Fair Value	403.1	521.4
Asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost Basis	173.2	88.2
Unrealized Gains	0.8	0.1
Unrealized Losses	(0.1)	(1.2)
Fair Value	$ 173.9	$ 87.1

Marketable Securities - Sched_2

Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Maturities within one year	$ 7,784.7	$ 8,114.8
Maturities after one year through five years	7,181.9	4,414.5
Maturities after five years	0.8	4.6
Total	$ 14,967.4	$ 12,533.9

Marketable Securities - Sched_3

Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value
Less than 12 Months	$ 12,339.2	$ 7,854.9
12 Months or Greater	1,667.5	4,157.5
Total	14,006.7	12,012.4
Unrealized Losses
Less than 12 Months	(0.8)	(9)
12 Months or Greater	(25.2)	(106.8)
Total	(26)	(115.8)
Corporate bonds
Fair Value
Less than 12 Months	6,351.7	2,363.3
12 Months or Greater	1,415.6	4,034.7
Total	7,767.3	6,398
Unrealized Losses
Less than 12 Months	(0.7)	(2.4)
12 Months or Greater	(23.7)	(102.5)
Total	(24.4)	(104.9)
U.S. government and government agency obligations
Fair Value
Less than 12 Months	5,799.9	4,780.6
12 Months or Greater	198.7	52.7
Total	5,998.6	4,833.3
Unrealized Losses
Less than 12 Months	(0.1)	(6)
12 Months or Greater	(1.2)	(2.6)
Total	(1.3)	(8.6)
Sovereign bonds
Fair Value
Less than 12 Months	46	12.4
12 Months or Greater	20.9	44.8
Total	66.9	57.2
Unrealized Losses
Less than 12 Months	0	(0.1)
12 Months or Greater	(0.2)	(0.8)
Total	(0.2)	(0.9)
Commercial paper
Fair Value
Less than 12 Months		636.8
12 Months or Greater		0
Total		636.8
Unrealized Losses
Less than 12 Months		(0.2)
12 Months or Greater		0
Total		(0.2)
Asset-backed securities
Fair Value
Less than 12 Months	141.6	61.8
12 Months or Greater	32.3	25.3
Total	173.9	87.1
Unrealized Losses
Less than 12 Months	0	(0.3)
12 Months or Greater	(0.1)	(0.9)
Total	$ (0.1)	$ (1.2)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	$ 14,967.4	$ 12,533.9
Corporate bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	7,767.3	6,398
U.S. government and government agency obligations
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	5,998.6	4,833.4
Sovereign bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	66.9	57.2
Commercial paper
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	557.6	636.8
Certificates of deposit
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	403.1	521.4
Asset-backed securities
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	173.9	87.1
Measured on a recurring basis
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	934.8	928.1
Total assets	17,210.4	14,439.4
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration	36.7	43.7
Measured on a recurring basis \| Unrestricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	1,232.1	864.5
Measured on a recurring basis \| Restricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	76.1	112.9
Measured on a recurring basis \| Corporate bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	7,767.3	6,398
Measured on a recurring basis \| U.S. government and government agency obligations
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	5,998.6	4,833.4
Measured on a recurring basis \| Sovereign bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	66.9	57.2
Measured on a recurring basis \| Commercial paper
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	557.6	636.8
Measured on a recurring basis \| Certificates of deposit
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	403.1	521.4
Measured on a recurring basis \| Asset-backed securities
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	173.9	87.1
Measured on a recurring basis \| Level 1
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	517.3	6.4
Total assets	1,825.5	983.8
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration	0	0
Measured on a recurring basis \| Level 1 \| Unrestricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	1,232.1	864.5
Measured on a recurring basis \| Level 1 \| Restricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	76.1	112.9
Measured on a recurring basis \| Level 1 \| Corporate bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 1 \| U.S. government and government agency obligations
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 1 \| Sovereign bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 1 \| Commercial paper
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 1 \| Certificates of deposit
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 1 \| Asset-backed securities
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 2
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	417.5	921.7
Total assets	15,384.9	13,455.6
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration	0	0
Measured on a recurring basis \| Level 2 \| Unrestricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	0	0
Measured on a recurring basis \| Level 2 \| Restricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	0	0
Measured on a recurring basis \| Level 2 \| Corporate bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	7,767.3	6,398
Measured on a recurring basis \| Level 2 \| U.S. government and government agency obligations
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	5,998.6	4,833.4
Measured on a recurring basis \| Level 2 \| Sovereign bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	66.9	57.2
Measured on a recurring basis \| Level 2 \| Commercial paper
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	557.6	636.8
Measured on a recurring basis \| Level 2 \| Certificates of deposit
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	403.1	521.4
Measured on a recurring basis \| Level 2 \| Asset-backed securities
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	173.9	87.1
Measured on a recurring basis \| Level 3
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	0	0
Total assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration	36.7	43.7
Measured on a recurring basis \| Level 3 \| Unrestricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	0	0
Measured on a recurring basis \| Level 3 \| Restricted
Assets, Fair Value Disclosure [Abstract]
Equity securities	0	0
Measured on a recurring basis \| Level 3 \| Corporate bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 3 \| U.S. government and government agency obligations
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 3 \| Sovereign bonds
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 3 \| Commercial paper
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 3 \| Certificates of deposit
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	0	0
Measured on a recurring basis \| Level 3 \| Asset-backed securities
Assets, Fair Value Disclosure [Abstract]
Available-for-sale debt securities	$ 0	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net unrealized gains (losses)	$ 134.5	$ (100.3)	$ 330.8	$ (295.9)
Securities owned not readily marketable	159.8		159.8		$ 74.3
Write-down in other income (expense)		$ 29
Level 2 \| Measured on a recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	1,577		1,577		1,528
Level 3 \| Measured on a recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	$ 47		$ 47		$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 856.6	$ 789.3
Work-in-process	1,230.1	1,121.8
Finished goods	164.6	147.3
Deferred costs	766.7	522.1
Total Inventories	$ 3,018	$ 2,580.5

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
Income Taxes (Details)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	10.20%	9.30%	8.60%	8.40%

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2024	Apr. 30, 2024	Jan. 31, 2023
Class of Stock [Line Items]
Remaining authorized repurchase amount	$ 2,893
Share Repurchase Program, January 2023
Class of Stock [Line Items]
Share repurchase program, authorized amount			$ 3,000
Share Repurchase Program, April 2024
Class of Stock [Line Items]
Share repurchase program, authorized amount		$ 3,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Share Repurchases (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Equity [Abstract]
Number of shares (in shares)	0.6	0.7	1.5	2.6
Total cost of shares	$ 738.3	$ 507.1	$ 1,637.7	$ 1,923.8

Statement of Cash Flows - Sched

Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 2,011.8	$ 2,730	$ 2,152.3
Restricted cash included in Other noncurrent assets	0		7.9
Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows	$ 2,011.8	$ 2,737.8	$ 2,160.2	$ 3,119.4

Statement of Cash Flows - Summa

Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details) - USD ($) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Accrued capital expenditures	$ 94	$ 98.9	$ 75.4	$ 70.8
Accrued contingent consideration in connection with acquisitions	$ 88	$ 106.5	$ 71.6	$ 135.5

Legal Matters (Details)

Legal Matters (Details)	Jul. 16, 2020 claim
'631 Patent
Loss Contingencies [Line Items]
Number of IPR filed	2